Form 4 Castle Biosciences Inc For: 6 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Castle Biosciences Inc. for July 6th. It mentions the company's stock symbol CSTL and its price performance, but provides no further details about the content of the Form 4 filing itself. The article also includes general market data and related news.
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan
Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold a total of 8,586 shares of Common Stock on July 1, 2026, through a pre-arranged Rule 10b5-1 trading plan. The shares were sold in two weighted-average price transactions at $24.40 and $24.78 per share. Following these sales, Oelschlager directly holds 21,874 shares and indirectly holds 97,251 shares through the Fritz Shorter Trust.
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock
Derek Maetzold, President and CEO of Castle Biosciences Inc. (NASDAQ: CSTL), sold 9,834 shares of company stock for approximately $238,916 through direct and indirect trusts, as reported in an SEC filing. Concurrently, he acquired 6,214 shares by exercising stock options as part of a Rule 10b5-1 trading plan adopted in December 2025. The transactions occurred while CSTL shares were trading near $24.26, with the company also announcing strong Q1 2026 revenue and advancements in its diagnostic tests.
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan
Castle Biosciences CEO Derek Maetzold, through associated entities, sold 9,836 shares of common stock at a weighted-average price of $24.29 per share on July 1, 2026, pursuant to a pre-arranged Rule 10b5-1 plan. Concurrently, he exercised options for 6,214 shares at $2.39 each. These transactions were identified as routine by analysts, involving the exercise of fully vested options and planned monetization, and do not suggest a significant change in insider sentiment.
The Technical Signals Behind (CSTL) That Institutions Follow
This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL), highlighting strong sentiment across all time horizons supporting an overweight bias. It details several AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels for near-term, mid-term, and long-term outlooks.
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL
The article focuses on the enterprise value to forward revenue of Castle Biosciences, Inc. (NASDAQ: CSTL). It appears to be a financial data point presented within the context of TradingView's platform, indicating analytical information for investors and traders.
Form 144 Castle Biosciences For: 1 July By Investing.com
This article announces the filing of Form 144 for Castle Biosciences (CSTL) on July 1st. It also includes current stock market data and various financial news headlines from Investing.com. The company's stock symbol is CSTL, and it shows a 3.61% increase.
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots
Multiple Rule 144 sale notices by Derek Maetzold and related trusts regarding CASTLE BIOSCIENCES INC (CSTL) have been reported, listing numerous small open-market dispositions of Common shares between April and June 2026. The sales, which include those from trusts like The Maetzold 2018 Remainder Trust and Derek Maetzold 2020 Irrevocable Trust, are characterized as routine liquidity events rather than a concentrated liquidation due to their granular nature. The SEC filing provides details on share counts and gross amounts for each transaction, without an explicit aggregate total.
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones
This article provides a precision trading analysis for Castle Biosciences Inc. (CSTL) as of June 25, 2026, highlighting a strong near-term sentiment with a long-term positive bias. It details an exceptional risk-reward setup targeting a 46.0% gain versus a 0.3% risk, along with specific institutional trading strategies including position trading, momentum breakout, and risk hedging, each with entry zones, targets, and stop-loss levels. The analysis is based on AI models and multi-timeframe signal analysis for various holding periods.
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086)
This article provides an overview of Castle Biosciences, Inc. (TRADEGATE:086) financial actuals and estimates, including income statement, balance sheet, and cash flow data, as well as analyst price targets. It also includes frequently asked questions regarding the company's stock, earnings, revenue, EBITDA, and employee count. Key financial figures like past earnings, estimated future earnings, and revenue for the last quarter are detailed.
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL)
This article provides an overview of Castle Biosciences, Inc. (NASDAQ:CSTL) stock performance, financial estimates, and analyst forecasts. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, along with insights into revenue and net income. The article also touches upon investment considerations like technical analysis ratings for the stock.
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down
Analyst price targets for Castle Biosciences (CSTL) have seen mixed revisions, with some targets lowered from the US$50 range to the mid-US$30s and US$40s, reflecting a more cautious outlook on growth and profitability. While some analysts maintain a "Buy" rating, citing strong revenue growth and market-leading margins, others have reduced their price targets due to concerns about the conversion of testing volumes to sustained earnings. Despite these adjustments, the fair value for CSTL remains stable at US$44.0, supported by consistent forecast revenue growth and refined net profit margin assumptions.
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Castle Biosciences' Chief Financial Officer, Frank Stokes, has been recognized as a 2026 CFO Awards honoree by the Houston Business Journal. This award acknowledges his financial leadership and contributions, including guiding the company through its Nasdaq IPO and multiple strategic acquisitions since 2017. Stokes was among 22 financial leaders from the Greater Houston area to receive this honor.
Castle Biosciences’ melanoma test outperforms risk tool
Castle Biosciences (NASDAQ:CSTL) announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the Melanoma Institute Australia nomogram in identifying low and high-risk melanoma patients, as published in Dermatology and Therapy. The company, with a strong gross profit margin of 78% and a current ratio of 6.75, maintains solid financials despite being down 43% year-to-date. Analysts have a "Strong Buy" rating with price targets indicating substantial upside, and InvestingPro suggests the stock is currently undervalued.
Roth Capital Initiates Castle Biosciences at Buy
Roth Capital has initiated coverage on Castle Biosciences with a "Buy" rating. This indicates a positive outlook from the investment firm regarding the company's stock. Investors will be watching for further details on the rationale behind this rating.
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL
This article focuses on the "Enterprise value to EBIT forward" metric for Castle Biosciences, Inc. (NASDAQ: CSTL) as listed on TradingView. It appears to be a financial data snippet rather than a comprehensive article, indicating a reporting of this specific financial ratio for the company.
Castle Biosciences test better spots melanoma patients who may skip surgery
Castle Biosciences announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the MIA nomogram in a prospective, multicenter study for identifying cutaneous melanoma patients who could safely avoid sentinel lymph node biopsy (SLNB). The i31-SLNB test accurately identified low-risk patients with a 2.6% observed SLN positivity rate, which is below the NCCN's 5% threshold, whereas the MIA nomogram showed a 5.8% positivity rate for its low-risk group. This improved accuracy, integrating gene expression profiles with clinical factors, can lead to more informed and risk-aligned patient care, potentially reducing unnecessary surgical procedures and associated complications.
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones
This article provides a precision trading analysis for Castle Biosciences Inc. (CSTL) based on AI models. It identifies a strong near-term sentiment potentially influencing a long-term positive bias, highlights an exceptional risk-reward setup, and outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strength, support, and resistance levels for the stock.
Roth Capital Initiates Castle Biosciences at Buy
Roth Capital has initiated coverage on Castle Biosciences Inc. with a "Buy" rating. As of June 25, 2026, the stock was trading at $22.82, showing a 5-day change of +3.16% and a year-to-date change of -41.26%. The average analyst target price for Castle Biosciences is $43.56, indicating a potential upside of 96.91% from its last closing price.
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL
This page from TradingView provides financial information for Castle Biosciences, Inc. (NASDAQ: CSTL), specifically focusing on its price-to-earnings forward ratio. The content indicates that the company's financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086
The article provides financial information for Castle Biosciences, Inc. (TRADEGATE:086), specifically focusing on its enterprise value to revenue forward metric. It lists the company on the Tradegate Exchange and indicates that the market is currently closed without any trades. The content seems to be a snapshot from a financial data platform offering an overview of the company's financials, news, community insights, and forecasts.
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL
The article references the enterprise value to EBITDA forward for Castle Biosciences, Inc. (NASDAQ: CSTL). It appears to be a stub or placeholder from TradingView, indicating financial data without providing specific figures. The content primarily consists of navigation and boilerplate text rather than detailed financial analysis.
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Castle Biosciences announced that its Chief Financial Officer, Frank Stokes, was named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is among 22 financial leaders recognized for their contributions and will be celebrated at an event on July 30. This recognition highlights his financial discipline and strategic vision, which have supported Castle Biosciences' growth, including its Nasdaq IPO and multiple acquisitions.
Castle Biosciences CFO Frank Stokes Named Houston Business Journal CFO Awards Honoree
Castle Biosciences Chief Financial Officer Frank Stokes has been honored by the Houston Business Journal as a 2026 CFO Awards recipient. This recognition highlights his leadership in the diagnostic company's growth, strategic development, and successful navigation through an initial public offering and multiple acquisitions since joining in December 2017. Stokes will be celebrated at an awards ceremony on July 30 and featured in the Houston Business Journal's July 31 editions.
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Castle Biosciences announced that its Chief Financial Officer, Frank Stokes, was named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is recognized for his financial leadership and contributions, including guiding the company through its Nasdaq IPO in 2019 and supporting its growth through strategic acquisitions. He will be celebrated at an awards event and featured in the Houston Business Journal in July.
Castle Biosciences CFO Frank Stokes named among 22 Houston finance leaders
Castle Biosciences (Nasdaq: CSTL) announced that its Chief Financial Officer, Frank Stokes, was recognized as a 2026 CFO Awards honoree by the Houston Business Journal. He is one of 22 financial leaders in Greater Houston acknowledged for their leadership and impact. Stokes has been CFO since December 2017, having guided the company through its 2019 Nasdaq IPO and supported its growth via strategic acquisitions, and will be celebrated at an event on July 30.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. announced that its Compensation Committee granted restricted stock units (RSUs) to 172 employees, covering an aggregate of 204,925 shares of common stock. These grants were made as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting after the first year and the remainder vesting annually in three equal installments.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. announced that its Compensation Committee granted restricted stock units (RSUs) to 172 employees, covering 204,925 shares of common stock. These grants were made as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting after the first year and the remainder in three equal annual installments, contingent on continued employment.
Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K
Castle Biosciences (CSTL) Chief Operating Officer Kristen M. Oelschlager sold 8,587 shares of common stock at a weighted-average price of $20.71 per share on June 16, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Oelschlager still directly holds 30,460 shares and indirectly holds 97,251 shares through The Fritz Shorter Trust, maintaining a significant equity position in the company. The sale, executed in multiple trades between $20.51 and $20.95, represents a moderate filing impact and negative sentiment from the article's AI summary.
Castle Biosciences Inc (CSTL) Institutional Confidence
Castle Biosciences Inc (CSTL) has an institutional shareholding score of 10.00, ranking 1st in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 91.06%, which is a 13.92% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.76% of outstanding shares.
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Castle Biosciences Inc (CSTL), noting its current valuation score of 7.97 and a ranking of 123 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -48.70, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Castle Biosciences president & CEO Derek J. Maetzold sells $86,193 stock
Derek J. Maetzold, President and CEO of Castle Biosciences Inc. (NASDAQ:CSTL), sold 4,172 shares of common stock for approximately $86,193 on June 15, 2026, while also acquiring 550 shares through stock option exercises. These transactions were executed under a Rule 10b5-1 plan, as the company's stock has dropped nearly 49% in the past six months but is considered undervalued by InvestingPro. Castle Biosciences recently reported strong Q1 2026 revenue and significant adoption for its TissueCypher Barrett’s Esophagus Test.
Castle Biosciences (CSTL) CEO Maetzold exercises options, trusts sell 4,172 shares
Castle Biosciences (CSTL) CEO Derek J. Maetzold recently exercised options to acquire 550 shares and, through associated family trusts, sold a total of 4,172 shares of common stock at a weighted-average price of $20.66 per share. These sales were conducted under a pre-scheduled Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, Maetzold directly holds 21,479 shares, with additional indirect holdings via various trusts.
Castle Biosciences president & CEO Derek J. Maetzold sells $86,193 stock By Investing.com
Castle Biosciences President and CEO Derek J. Maetzold sold 4,172 shares of common stock totaling $86,193 on June 15, 2026, while also acquiring 550 shares through stock option exercise. These transactions were executed under a Rule 10b5-1 plan, and the stock is considered undervalued by InvestingPro analysts despite a 49% decline over six months. The company recently reported strong Q1 2026 revenue growth and its TissueCypher Barrett’s Esophagus Test exceeded 100,000 orders.
Castle Biosciences president & CEO Derek J. Maetzold sells $86,193 stock
Derek J. Maetzold, President and CEO of Castle Biosciences Inc., sold 4,172 shares of common stock for approximately $86,193, while also acquiring 550 shares through stock option exercise. These transactions were executed under a Rule 10b5-1 plan, and the stock is considered undervalued despite recent declines. The company recently reported strong first-quarter 2026 earnings and progress with its TissueCypher Barrett’s Esophagus Test.
Castle Biosciences’ Barrett’s esophagus test reaches 100k orders By Investing.com
Castle Biosciences Inc. announced that its TissueCypher Barrett’s Esophagus Test has exceeded 100,000 clinical test orders. The test identifies patients at risk of progression to high-grade dysplasia or esophageal adenocarcinoma, using an AI-derived approach to analyze biopsies. Despite recent stock volatility, the company maintains a strong gross profit margin and is considered undervalued by InvestingPro analysis, having also reported significant revenue growth in Q1 2026.
CSTL (NASDAQ) Rule 144 notice: director sale notice for 4,152 shares
Castle Biosciences (CSTL) has filed a Rule 144 notice indicating proposed sales related to an exercise of stock options. The filing notes 4,152 shares from an option exercise dated June 16, 2026, and also lists 25,759 restricted and performance stock units with a December 31, 2025 date. This notice describes potential future transactions rather than completed sales, with Morgan Stanley Smith Barney LLC identified as the broker.
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher® Barrett's Esophagus Test has surpassed 100,000 clinical orders. This AI-derived precision medicine test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, helping clinicians tailor management decisions. The milestone highlights the growing use of personalized risk assessment for patients with this condition.
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher® Barrett's Esophagus Test has surpassed 100,000 clinical orders. This AI-derived precision medicine test helps predict a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, enabling clinicians to tailor management decisions. The milestone highlights the growing adoption of personalized risk assessment in managing Barrett's esophagus.
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher® Barrett's Esophagus Test has surpassed 100,000 clinical orders. This AI-derived precision medicine test predicts a patient's five-year risk of progression from Barrett's esophagus (BE) to high-grade dysplasia or esophageal adenocarcinoma, enabling clinicians to tailor management decisions. The company highlights the growing adoption of TissueCypher to provide personalized risk information and improve patient outcomes.
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced its TissueCypher® Barrett's Esophagus Test has surpassed 100,000 clinical orders. This AI-derived precision medicine test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, helping clinicians tailor management decisions. The milestone highlights the growing adoption of TissueCypher in providing personalized risk assessment, enabling earlier identification and treatment for high-risk patients.
Technical Reactions to CSTL Trends in Macro Strategies
This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL) focusing on its technical reactions to macro trends. It indicates a neutral sentiment in the near and mid-term, with a long-term positive bias but elevated downside risk due to a lack of additional long-term support. The analysis provides three institutional trading strategies tailored with risk management for different holding periods.
Castle Biosciences (CSTL) CEO sells shares and exercises options under 10b5-1 plan
Castle Biosciences CEO Derek J. Maetzold reported exercising stock options and selling shares of Castle Biosciences Inc. common stock under a pre-arranged Rule 10b5-1 trading plan. He acquired 6,214 shares through option exercises at $2.39 per share and disposed of 9,836 shares in open-market transactions at a weighted-average price of $20.8570 per share. These sales included holdings from various family and grantor trusts, with Maetzold's direct holdings totaling 21,479 shares following the transactions.
CSTL: Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption
Castle Biosciences, Inc. (CSTL) raised its 2026 revenue guidance following strong Q1 growth in its core diagnostic tests and robust margins. The company aims to expand into dermatology and GI markets with new product launches and pipeline innovations. Future reimbursement and adoption are anticipated to be supported by legislative trends and the clinical value of its tests.
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units
Castle Biosciences director Ellen Goldberg was granted 11,766 Restricted Stock Units (RSUs) as a compensation-related equity award. Each RSU represents one share of the company's common stock, and the RSUs will vest in full on the earlier of May 28, 2027, or the day before the next Annual Meeting of Stockholders. This transaction is categorized as an acquisition of derivative securities, not an open-market purchase or sale.
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units
Castle Biosciences director Harrison Miles was awarded 11,766 Restricted Stock Units (RSUs) on May 28, 2026, as part of his equity compensation. These RSUs, each representing one share of common stock, will vest fully on the earlier of May 28, 2027, or the day before the next Annual Meeting of Stockholders. This transaction is considered a routine grant and does not signal a change in market sentiment.
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant
Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units (RSUs) as equity compensation. These RSUs, which convert into common stock at no purchase price, will vest fully on the earlier of May 28, 2027, or the day before the company's next Annual Meeting of Stockholders. This grant is a routine equity compensation and aligns Olson's interests with those of the shareholders.
Director at Castle Biosciences (CSTL) granted 11,766 RSUs
Rodney Cotton, a director at Castle Biosciences (CSTL), was granted 11,766 Restricted Stock Units (RSUs) as compensation, as detailed in a recent Form 4 SEC filing. Each RSU represents the right to receive one share of common stock and will vest in full on the earlier of May 28, 2027, or the day before the company's next annual stockholders' meeting. This award is a compensation grant, not an open-market purchase, and is intended to align his interests with the company's long-term success.
Director at Castle Biosciences (CSTL) receives 11,766 RSU equity award
Castle Biosciences director Daniel Bradbury was granted 11,766 Restricted Stock Units (RSUs) on May 28, 2026. These RSUs will vest in full on the earlier of May 28, 2027, or the day before the next Annual Meeting of Stockholders. Following this award, Bradbury holds 11,766 RSUs directly, each representing one share of Castle Biosciences common stock.
Castle Biosciences (NASDAQ: CSTL) grants 11,766 RSUs to director
Castle Biosciences (NASDAQ: CSTL) has granted 11,766 Restricted Stock Units (RSUs) to director Cole G. Bradley. This equity compensation award, detailed in a Form 4 filing, vests fully on the earlier of one year from May 28, 2027, or the day before the next Annual Meeting of Stockholders following the grant. Each RSU represents the right to receive one share of the company's common stock, reflecting a compensation-related grant rather than an open-market purchase.
